Previous close | 24.73 |
Open | 24.73 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 270.00 |
Expiry date | 2025-01-17 |
Day's range | 24.73 - 24.73 |
Contract range | N/A |
Volume | |
Open interest | 1 |
WILMINGTON, Mass., May 02, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality.
ICLR vs. CRL: Which Stock Is the Better Value Option?
Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.